

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1430
Abstractia, Viginia 22113-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/854,906	05/14/2001	Steven F. Sukits	37174/8	7599
26171 75	90 02/27/2004	SIPE	EXAMINER	
FISH & RICHARDSON P.C.		10	BORIN, MICHAEL L	
1425 K STREE	I, N.W.	MAR 2 9 2004 8	ART UNIT	PAPER NUMBER
WASHINGTON, DC 20005-3500		/ Putt 1	1631	
		THE TRADEMEN OF	DATE MAILED: 02/27/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO	
09/854906				
		ţ		
			EXAMINER	
		Michael Borin	· · · · · · · · · · · · · · · · · · ·	
		ART UNIT	PAPER NUMBER	
		1631		
		t DATE MAILEC		

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotides and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). See 37 CFR 1.821 (d). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the following reasons:

This application contains amino acid sequences; however, the application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c) and a computer readable form.

Any inquiry concerning this communication should be directed to Examiner M.L. Borin, Art Unit 1631 whose telephone number is (703) 305-4506.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

MICHAEL BORIN PH.D. PRIMARY EXAM TR



Application No.: 09/854906

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and
at 55 FR 18230, May 1, 1990.
2.This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). A paper copy is in the file but is not in accordance with new
Sequence Listing Rules.
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the
content of the computer readable form does not comply with the requirements of
37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence
Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of
the
"Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An initial computer readable form (CRF) copy of the "Sequence Listing".
An initial as substitute person control the "Control of the "Control of the "Control of the control of the cont
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
The birdy into the openinguism.
A statement that the content of the paper and computer readable copies are the same and,
where applicable, include no new matter, as required by 37 C.F.R. 1.021(e) of 1.621(f) of
1.821(g) or
1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Dulon Intermediate and (702) 200 4040
For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE